Incannex Healthcare is a drug manufacturers - specialty & generic business based in the US. Incannex Healthcare shares (IXHL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.79 – an increase of 12.93% over the previous week. Incannex Healthcare employs 9 staff and has a trailing 12-month revenue of around $12,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.79 |
|---|---|
| 52-week range | $0.80 - $12.68 |
| 50-day moving average | $1.80 |
| 200-day moving average | $2.90 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.79 from 2024-10-15
| 1 week (2024-10-09) | 12.93% |
|---|---|
| 1 month (2024-09-16) | 2.87% |
| 3 months (2024-07-16) | -29.80% |
| 6 months (2024-04-16) | -26.34% |
| 1 year (2023-10-16) | 86.46% |
|---|---|
| 2 years (2022-10-14) | -58.28% |
| 3 years (2021-10-12) | N/A |
| 5 years (2019-10-12) | N/A |
| Revenue TTM | $12,000 |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -56.97% |
| Return on equity TTM | -115.22% |
| Profit margin | 0% |
| Book value | $0.64 |
| Market Capitalization | $31.6 million |
TTM: trailing 12 months
Incannex Healthcare's shares were split on a 1:4 basis on 29 November 2023. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Incannex Healthcare shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Incannex Healthcare shares which in turn could have impacted Incannex Healthcare's share price.
Over the last 12 months, Incannex Healthcare's shares have ranged in value from as little as $0.8 up to $12.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incannex Healthcare's is 2.271. This would suggest that Incannex Healthcare's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Incannex Healthcare's beta into context you can compare it against those of similar companies.
Incannex Healthcare Inc. , a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Hea.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.